Alerta

METHODS OF TREATING A PATIENT WITH AN INFLAMMATORY BOWEL DISEASE

Resumen de: AU2024362918A1

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE

Resumen de: AU2024354463A1

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

SYSTEM AND METHOD FOR DETERMINING A STOOL CONDITION

Resumen de: US20260114804A1

0000 Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.

TL1A结合分子及其应用

Resumen de: CN121930341A

本发明提供了TL1A结合分子及其应用。具体地，本发明提供了抗TL1A单域抗体或其抗原结合片段，其能够与人和食蟹猴TL1A结合，阻断TL1A/DR3通路，但不影响TL1A与TL1A/DR3通路的天然阻断剂DcR3的结合。本发明的抗TL1A单域抗体或其抗原结合片段与TL1A的结合具有pH依赖性，更有利于在体内长期循环，延长半衰期。因此，本发明的抗TL1A单域抗体或其抗原结合片段可作为新型治疗剂，应用于免疫炎症相关疾病的治疗。

SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof

Resumen de: US20260109755A1

0000 The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

Application of reagent for detecting tsRNA molecular marker in intestinal mucosa tissue in preparation of Crohn disease diagnostic kit

Resumen de: CN121896348A

The invention belongs to the technical field of biological medicine, and particularly discloses application of a reagent for detecting a tsRNA molecular marker in intestinal mucosa tissue to preparation of a Crohn disease diagnostic kit, the reagent is characterized in that the tsRNA molecular marker is tRF-28-PW5SVP9N1503, the sequence of the tsRNA molecular marker is GCCGTGATAGTGGTTAGTACTCT, the reagent for detecting the tsRNA molecular marker in the intestinal mucosa tissue comprises tRF-28-PW5SVP9N1503 fluorescent quantitative PCR upstream and downstream primers, and the primer sequence of the tsRNA molecular marker in the intestinal mucosa tissue is shown in the description. The upstream primer is AATG CCGTGATCGTATAGTGGTT, and the downstream primer is TATCCTTGTTGACGACTGGTTGAC, and the downstream primer is The method has the advantages that absolute quantitative detection of target molecules can be rapidly and accurately completed only with a small amount of samples, and the method is used for early screening and identification of Crohn's disease and is high in sensitivity and specificity.

Method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry

Resumen de: CN121878075A

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

METHODS AND SYSTEMS FOR DETECTION OF PRE-CANCER

Resumen de: WO2026080407A1

Provided herein are methods and systems for detection of precancer or cancer. The method may comprise using cell-free nucleic acids. The methods may comprise assaying nucleic acids. The method may comprise extracting cell-free nucleic acids. The methods may comprise generating libraries based at least on cell-free nucleic acids.

一种炎症性肠病诊断用细胞外囊泡蛋白质标志物及应用

Resumen de: CN121831162A

本发明涉及分子诊断技术领域，公开了一种炎症性肠病诊断用细胞外囊泡蛋白质标志物及应用，该标志物源于血浆细胞外囊泡膜蛋白，包括用于诊断克罗恩病的组分I、诊断溃疡性结肠炎的组分II及鉴别用的组分III。本发明采用聚合物沉淀结合超速离心法提取囊泡，利用抗体寡核苷酸偶联探针及邻近条形码分析技术进行高通量检测。结合机器学习算法对囊泡亚群进行聚类分析，应用该标志物制备的试剂盒，通过检测特定蛋白组合及细胞外囊泡亚群比例，实现了炎症性肠病的无创筛查、早期诊断及亚型精准鉴别，有效解决了现有单一标志物诊断盲区与个体异质性问题，具有高灵敏度、高特异性及非侵入性优势。

Multi-constraint adaptive multi-modal fusion inflammatory bowel disease risk prediction method

Resumen de: CN121839141A

The invention provides a multi-constraint adaptive multi-modal fusion inflammatory bowel disease risk prediction method, which is applied to the crossing field of medical data processing and machine learning and is suitable for early diagnosis and clinical risk stratification of inflammatory bowel diseases. According to the method, multi-modal omics data related to the inflammatory bowel disease is collected, and a three-level bioinformatics filtering strategy is adopted for preprocessing; each piece of preprocessed modal data is coded, and modal orthogonal constraint is applied to retain modal specificity; dual-stage dynamic fusion is realized through a hierarchical attention mechanism, and modal weights are adaptively distributed; supervised comparative learning and maximum mean value difference loss are introduced, and feature discrimination and distribution consistency are enhanced; and finally, outputting an inflammatory bowel disease risk prediction result based on the fusion features. According to the method, high-dimensional redundant features are effectively compressed, the overfitting risk is reduced, modal specificity and complementarity are considered, the model generalization ability and subtype discrimination precision are improved, and reliable technical support is provided for early diagnosis of the inflammatory bowel disease.

Crohn disease early diagnosis marker screening method fusing multiple omics data

Resumen de: CN121838867A

The invention discloses a Crohn disease early diagnosis marker screening method fused with multi-omics data. The method comprises the following steps: constructing a Crohn disease evolution time sequence specificity multi-omics sample set, and synchronously obtaining genome, transcriptome, proteome and metabolome data through longitudinal sampling; a deep multi-omics time sequence fusion network model is constructed and applied to screen a candidate marker set, the network realizes multi-dimensional data deep integration through a multi-omics feature coding layer and a cross-omics cross attention fusion layer, and an evolution law of markers is captured through a time sequence dynamic modeling layer; the technical problems that in an existing marker screening method, multi-omics data integration is shallow, disease dynamic time sequence information is neglected, and a verification system is incomplete are solved, and the Crohn disease early diagnosis marker with high sensitivity and specificity can be efficiently and accurately screened out from complex multi-omics data; and the accuracy and clinical transformation potential of early diagnosis are remarkably improved.

Method and system for detecting relation between full sibs and half sibs of poultry

Resumen de: CN121811960A

The invention discloses a poultry full-sib and half-sib relationship detection method and system, and relates to poultry breeding. The method comprises the following steps: obtaining samples of N poultry individuals in a poultry group to be detected, and extracting DNA (Deoxyribose Nucleic Acid); performing genetic typing on N poultry individuals by using a high-density SNP chip to obtain a genotype matrix M; performing quality control on the genotype matrix M, and filtering the SNP markers with the detection rate lower than a first preset threshold value or the minimum allele frequency MAF lower than a second preset threshold value to obtain a genotype matrix after quality control; according to the genotype matrix, calculating an IBS similarity coefficient and a genome genetic relationship coefficient GRC between any two individuals i and j; according to the poultry with known genetic relationship, IBS similarity coefficient distribution and genome genetic relationship coefficient GRC distribution of full-sib, half-sib and non-sib relationships are respectively counted, and 95% confidence interval of each category is calculated. The method improves the classification precision.

Differentiation Method for an Intestinal Epithelial Monolayer Model Derived from Duodenal Organoids of Crohns Disease Patients

Resumen de: KR20260045660A

본 발명은 크론병 환자 십이지장 오가노이드 유래 장 상피 단층 모델의 분화 방법에 관한 것으로, 발명의 장 상피 단층 모델은 3차원 십이지장 오가노이드로부터 해리된 단일 세포에 기초하여 분화를 유도한 것으로, 다양한 장 상피 세포 유형을 포함하고 내강(lumen)에 대한 접근성을 제공한다. 또한, 본 모델은 실제 환자 장 점막의 구조와 기능을 효과적으로 모사할 수 있어 염증성 장질환을 포함한 다양한 장 질환의 병태생리 연구뿐만 아니라, 후보 물질의 효능 및 안전성을 평가하는 데 유용하게 활용될 수 있다.

METHODS OF DETECTING MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS

Resumen de: WO2026064841A1

The present invention relates in part to methods of detecting Mycobacterium avium subsp. paratuberculosis in ruminant animals and markers for use in such methods.

Method of diagnosing a dysbiosis

Resumen de: AU2026201512A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS). eb e b

N-ACYL AMIDES AND ANALOGS

Resumen de: WO2026072849A2

The present disclosure provides pharmaceutical compositions, dosage forms comprising the pharmaceutical composition, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, and treating colorectal cancer in a subject in need thereof, comprising administering the pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.

Preparation method of non-metal magnetic resonance imaging nano diagnosis and treatment agent with controllable morphology

Resumen de: CN121754690A

The invention belongs to the technical field of magnetic resonance imaging nano diagnosis and treatment agents, and particularly relates to a preparation method of a shape-controllable nonmetal magnetic resonance imaging nano diagnosis and treatment agent. According to the preparation method, 2-(perfluorooctyl) ethyl methacrylate (HDFDMA) and methacrylic acid-2, 2, 6, 6-tetramethyl-4-piperidinyl ester (m-TEMPO) are taken as monomers to prepare shape-controllable sugarcoated haw-shaped nano-particles (WNPT), electronegative tannic acid (TA) is loaded after oxidation, and the shape-controllable sugarcoated haw-shaped nano-particles are prepared through a polymerization-induced self-assembly method. The nanometer diagnosis and treatment agent TA (at) WNPT with a magnetic resonance imaging (MRI) function and a colitis treatment function is obtained. According to the method disclosed by the invention, polymerization and assembly are synchronously carried out under the condition of high concentration, and the morphology, size and surface chemical characteristics of the nanoparticles are accurately regulated and controlled. It is proved for the first time that in the nonmetal MRI probe, compared with spherical particles, the sugarcoated haw-shaped structure can remarkably improve the MRI performance.

Methods and Treatment Involving Excess Free LIGHT

Resumen de: US20260085112A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

DIETARY MACRO/MICRONUTRITIONAL COMPOSITIONS AND APPLICATIONS THEREOF

Resumen de: US20260083739A1

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

CFDNA AS BIOMARKER FOR INFLAMMATORY BOWEL DISEASES

Resumen de: WO2024236584A1

Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.

Biomarker for ulcerative colitis and colorectal cancer related to ulcerative colitis and application of biomarker

Resumen de: CN121718633A

The invention discloses a biomarker for ulcerative colitis and colorectal cancer related to the ulcerative colitis and application of the biomarker, and belongs to the field of molecular biological technology and medicine. The invention discloses an effect of E3 ubiquitin ligase TRIM50 in ulcerative colitis and colorectal cancer related to the ulcerative colitis. The key regulation effect of TRIM50 in UC and UC-CRC is found and verified for the first time, and the potential of TRIM50 as a novel auxiliary detection biomarker and a therapeutic target is defined. The expression level of TRIM50 can be used as a specific biomarker of UC and UC-CRC, and is applied to early screening of diseases, disease assessment or prognosis; targeted regulation of the expression or activity of TRIM50 is expected to become a new strategy for inhibiting the malignant progress of UC-CRC, and a solid theoretical basis and a screening direction are provided for developing innovative drugs.

Biomarker combination and application thereof in predicting risk of Crohn disease

Resumen de: CN121718631A

The invention relates to the technical field of biological medicines, and particularly discloses a biomarker composition and application thereof in predicting the risk of Crohn's disease. The reagent is at least used for detecting more than one group of biomarkers in a first group, a second group and a third group, the first group of biomarkers at least comprises two of APOC1, CDH13, CNDP1, CPB2, MEGF8 and RARRES1, the second group of biomarkers at least comprises two of ALAD, ENPP2, ITIH4, NAV2, PRG2 and SLIT2, and the third group of biomarkers at least comprises two of CFP, GLIPR2, IGHV3-13, PRDX1, SIAE and SNX25. Predictive and/or diagnostic kits developed based on these biomarkers can distinguish healthy individuals, preclinical, early and progression Crohn's disease risks.

Urine marker for ulcerative colitis as well as analysis method and application thereof

Resumen de: CN121721169A

The ulcerative colitis urine marker can be effectively used for diagnosis and treatment monitoring of ulcerative colitis, and is non-invasive, high in sensitivity and accurate and reliable in result. The ulcerative colitis urine marker at least comprises one of an immune globulin kappa connecting region 1, an immune globulin kappa variable region 6-21 and the like; the urine marker can be used for disease monitoring and at least comprises one of protein 4 rich in glutamic acid, presumed teratoma-derived growth factors 3 and the like.

Application of HIF-1a in inhibition of HvKp liver abscess in high glucose state

Resumen de: CN121695122A

The invention belongs to the technical field of biomedical research, and particularly relates to an effect of HIF-1a in liver abscess caused by high-toxicity klebsiella pneumoniae infection in a high glucose state. The invention aims to solve the main problem of providing a treatment target for liver abscess caused by high-toxicity klebsiella pneumoniae infection related to diabetes mellitus. As a transcription factor for regulating in-vivo balance, HIF-1a participates in maintaining the integrity of an epithelial barrier, and it is proved that HIF-1a is not reported in type 2 diabetes mellitus in alcoholic hepatitis, inflammatory bowel disease and other models through the anti-inflammatory and antimicrobial functions of immune cells. Modeling finds that the expression of HIF-1a in a type 2 diabetes mellitus combined high-virulence klebsiella pneumoniae infection model is reduced, and inflammation can be obviously relieved after intervention by adding an HIF-1a activating agent. HIF-1a is prompted to be capable of serving as a treatment target of the diabetes-related high-toxicity klebsiella pneumoniae liver abscess.

Application of ZEB1 in analysis and treatment of Crohn disease related diseases

Nº publicación: CN121700056A 20/03/2026

Solicitante:

GUIZHOU PROVINCIAL PEOPLES HOSPITAL
UNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIV SCI & TECH
\u8D35\u5DDE\u7701\u4EBA\u6C11\u533B\u9662
\u534E\u4E2D\u79D1\u6280\u5927\u5B66\u540C\u6D4E\u533B\u5B66\u9662\u9644\u5C5E\u534F\u548C\u533B\u9662

Resumen de: CN121700056A

The invention belongs to the technical field of biology, and relates to application of ZEB1 in analysis and treatment of Crohn disease related diseases. Specifically, the invention discloses application of a reagent for detecting the expression level of ZEB1 in preparation of a product for analyzing the severity of Crohn's disease and the risk and severity of intestinal fibrosis stenosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis. The reagent for inhibiting ZEB1 expression is applied to preparation of products for inhibiting Crohn's disease complicated with intestinal fibrosis or stenosis. The invention determines that ZEB1 can be used as a biomarker of intestinal fibrosis of Crohn's disease, the expression level of ZEB1 is associated with the risk and severity of intestinal fibrosis or intestinal fibrosis stenosis complicated by Crohn's disease, and a new method is provided for clinically evaluating the risk and severity of disease. Meanwhile, it is clear that ZEB1 can be used as a target spot for treating Crohn's disease complicated with intestinal fibrosis or intestinal fibrosis stenosis.